MedTech company wins prestigious design award for ground-breaking blood-testing device

This post was originally published on this site

Denmark, Hovedstaden – 07-11-2019 (PRDistribution.com) — Today in Sidney, Australia, the just five-year old Danish- and Taiwan-based medical device company BluSense Diagnostics won Australia’s Good Design Award for its innovative blood testing device, BluBox. The young company has developed a diagnostics tool for emerging markets that can quickly identify the dengue and zika viruses from just one drop of blood.

“We’re very excited about winning this award, because it’s yet another international recognition of what we do. It proves that our device is solid, innovative, and fully functional. Winning this award serves as an endorsement towards the clinicians we’re meeting with to showcase the usability and human-centric design of BluBox and our patented technology,” says Filippo Bosco, CEO and one of the three founders of BluSense Diagnostics based in Copenhagen, Denmark.It usually takes MedTech companies many years to develop products and get them ready to market, however, BluSense Diagnostics has proven an exception to the rule. From idea to the final working product used by clinicians today, it took the young company less than three years to have the first version of the portable BluBox ready for market.For use with the BluBox, BluSense Diagnostics has also developed the ViroTrack – a proprietary cartridge which analyses a single drop of blood from the patient. Once the cartridge is inserted into the BluBox it quickly and quantitatively measures the specific biomarkers in the blood for several different viruses, thereby identifying the infection. The speed and high reliability of this diagnostic tool is unmatched today, helping physicians to diagnose patients much more quickly than using more traditional methods. Today, BluSense Diagnostics is able to quickly diagnose dengue fever as well as the zika and chikungunya viruses – and there are more to come.“Winning this award also attracts more investors to fund our continued development and expansion of the portfolio of diseases we can test from just one drop of blood. There’s a huge potential in our technology,” explains Filippo Bosco.Praised by the juryThe annual Good Design Awards is Australia’s most prestigious international award for design and innovation, with a proud history dating back to 1958. The Good Design Awards jury spent several days evaluating each entry according to a strict set of design criteria, covering ‘good design’, ‘design innovation’ and ‘design impact’. Projects receiving a Good Design Award must demonstrate excellence in all areas and convince the jury they are worthy of recognition. The Good Design Awards jury praised BluBox, commenting: “A potential game changer that scores high in every area. The BluBox involves innovation at every stage in the design process, including at the most fundamental level of developing an entirely new detection method that was able to be adapted to available sensing technologies and packaged into a robust and portable design. This is likely to have a major impact upon health in remote tropical locations with limited access to skilled clinicians and limited access to major diagnostic centres. When patients already need to undertake difficult travel to reach any form of medical assistance, the ability to achieve same-day diagnosis for immediate commencement of treatment is game changing in enabling remote communities to access modern treatments. Highly innovative solution to a big problem facing humanity. The scale of impact in addressing the human health issues related to infectious diseases across the globe is huge.”The Good Design Awards attracted a record number of submissions, with close to 700 design projects evaluated for this year’s international design awards. For further information, please contact:Filippo Bosco, CEO and co-founder of BluSense Diagnostics on +45 53 23 46 69.About BluSense Diagnostics:BluSense Diagnostics was founded in 2014 and has offices in Denmark and Taiwan. The spin-out company from the Technical University of Denmark (DTU) is committed to providing scalable and innovative diagnostic products on a global scale. About Good Design Australia and Australia’s Good Design Awards:Good Design Australia is an international design promotion organisation responsible for managing Australia’s annual Good Design Awards and other signature design events. With a proud history that dates back to 1958, Good Design Australia remains committed to promoting the importance of design to business, industry, government and the general public, and the critical role it plays in creating a better, safer and more prosperous world.www.good-design.orgEarlier wins for BluSense Diagnostics:It’s not the first award BluSense Diagnostics has won, but it’s the first for the design of a product (BluBox). Back in September 2018 the young MedTech company also won the prestigious Nordic Stars 2018 Award for its outstanding innovation and entrepreneurial skills demonstrated in developing a point-of-care platform for the diagnosis of life-threatening diseases. And in December 2017 BluSense Diagnostics was announced the Winner of Colossus INNO 2017 competition for the most innovative and impactful technology for South East Asia.

Media Contacts:

Company Name: BluSense Diagnostics
Full Name: Uffe Erup Larsen
Phone:
Email Address: Send Email
Website: http://www.blusense-diagnostics.com/

For the original news story, please visit https://prdistribution.com/news/medtech-company-wins-prestigious-design-award-for-ground-breaking-blood-testing-device.html.

Recommended For You

mm

About the Author: Sidney Martin

Sidney Marin Is a researcher and law student at York University (TORONTO). He has worked as the Director of the Graduate Lawyering Program. He worked for American law firms in Moscow, Russia for three years. Hegraduated from Columbia Law School, Columbia School of International and Public Affairs and Harvard College. He research interest is in human rights and health law, with a particular focus on the law and policy of vaccination.